Bausch Health Companies BHC Salix — Revenue
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch Health Companies in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Bausch Health Companies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bausch Health Companies's salix — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bausch Health Companies's salix — revenue?
- Bausch Health Companies (BHC) reported salix — revenue of $639M in Q1 2026.
- How has Bausch Health Companies's salix — revenue changed year-over-year?
- Bausch Health Companies's salix — revenue increased by 17.9% year-over-year, from $542M to $639M.
- What is the long-term trend for Bausch Health Companies's salix — revenue?
- Over 4 years (2021 to 2025), Bausch Health Companies's salix — revenue has grown at a 5.6% compound annual growth rate (CAGR), from $2.07B to $2.58B.
- What does salix — revenue mean?
- Represents the total gross revenue generated from the sale of pharmaceutical products and services within the Salix segment, net of returns and allowances. This is the primary indicator of the segment's market demand and commercial success in the gastroenterology and hepatology markets. It serves as the top-line performance metric for evaluating the segment's contribution to total company revenue.